| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6193689 | Practical Radiation Oncology | 2014 | 7 Pages |
Abstract
Following SABR for non-small cell lung cancer, VCP was associated with high cumulative dose to the VN in 1 patient and a moderately high dose to the VN and RecLN in another patient with rheumatoid arthritis and connective tissue disease. Particularly in the setting of reirradiation or connective tissue disease, potential toxicity to the VN or RecLN should be considered.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
David Benjamin MD, PhD, Nicholas MD, PhD, Peter G. PhD, Maximilian MD, PhD, Billy W. MD, PhD,